Neuroimaging in brain tumors;Neuroimagen de los tumores cerebrales

Revista Espanola de Medicina Nuclear

Volumn 30, Issue 1, 2011, Pages 47-65

  Arbizu, J ^a   Dominguez P D ^a   Diez Valle, R ^a   Vigil, C ^a   Garcia Eulate R ^a   Zubieta, J L ^a   Richter, J A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

CT; Diffusion; Diffusion tensor imaging; F DOPA; FDG; FET; Functional MRI; Methionine; MR spectroscopy; MRI; Perfusion; PET; SPECT; Thallium; Tractography

Indexed keywords

6 FLUORODOPA F 18; FLUROETHYLTYROSINE F 18; METHIONINE C 11; THALLIUM 201; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION TENSOR IMAGING; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; DIFFUSION TENSOR IMAGING; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY, INTERVENTIONAL; RADIOPHARMACEUTICALS; SURGERY, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79251593871     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/j.remn.2010.11.001     Document Type: Article

References (74)

1. Louis D., Ohgaki H., Wiestler O., Cavenee W., Burger P., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
2. Kelly P.J. Computed tomography and histologic limits in glial neoplasms: tumor types and selection for volumetric resection. Surg Neurol. 1993, 39:458-465.
3. Sanai N., Berger M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008, 62:753-764. discussion 264-266.
4. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7:392-401.
5. Diez-Valle R, Tejada S, Idoate Gastearena MA, de Eulate R, Echvarri P, Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol. 2010 (in press).
6. Stummer W., Reulen H.J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C., et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008, 62:564-576. discussion 564-76.
7. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-996.
8. Tovi M., Hartman M., Lilja A., Ericsson A. MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens. Acta Radiol. 1994, 35:495-505.
9. McKnight T., von dem Bussche M.H., Vigneron D., Lu Y., Berger M., McDermott M., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002, 97:794-802.
10. Ganslandt O., Stadlbauer A., Fahlbusch R., Kamada K., Buslei R., Blumcke I., et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery. 2005, 56(2 Supl):291-298.
11. Miwa K., Shinoda J., Yano H., Okumura A., Iwama T., Nakashima T., et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004, 75:1457-1462.
12. 11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004, 10:7163-7170.
13. Pirotte B.J., Levivier M., Goldman S., Massager N., Wikler D., Dewitte O., et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009, 64:471-481. discussion 481.
14. 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004, 101:476-483.
15. Wong T.Z., Turkington T.G., Hawk T.C., Coleman R.E. PET and brain tumor image fusion. Cancer J. 2004, 10:234-242.
16. Arbizu J., Garrastachu P., Dominguez I., et al. PET en tumores del SNC. Medicina Nuclear en la práctica clínica 2008, 695-705. Aula Médica, Madrid. A. Soriano, J. Martín-Comín, A.M. García Vicente (Eds.).
17. Bernard F., Romsa J., Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Sem Nucl Med. 2003, 33:148-162.
18. Kim H.S., Jahng G.H., Ryu C.W., Kim S.Y. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol. 2009, 30:1574-1579.
19. Li C., Ai B., Li Y., Qi H., Wu L. Susceptibility-weighted imaging in grading brain astrocytomas. Eur J Radiol. 2010, 75:e81-e85.
20. Horsk A., Barker P.B. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am. 2010, 20:293-310.
21. Gupta A., Shah A., Young R.J., Holodny A.I. Imaging of brain tumors: functional magnetic resonance imaging and diffusion tensor imaging. Neuroimaging Clin N Am. 2010, 20:379-400.
22. Fandino J., Kollias S.S., Wieser H.G., Valavanis A., Yonekawa Y. Intraoperative validation of functional magnetic resonance imaging and cortical reorganization patterns in patients with brain tumors involving the primary motor cortex. J Neurosurg. 1999, 91:238-250.
23. Thompson G., Mills S.J., Stivaros S.M., Jackson A. Imaging of brain tumors: perfusion/permeability. Neuroimaging Clin N Am. 2010, 20:337-353.
24. Latour L.L., Svoboda K., Mitra P.P., Sotak C.H. Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci U S A. 1994, 91:1229-1233.
25. Omuro A.M., Leite C.C., Mokhtari K., Delattre J.Y. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006, 5:937-948.
26. Law M., Yang S., Wang H., Babb J.S., Johnson G., Cha S., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003, 24:1989-1998.
27. Delbeke D., Meyerowitz C., Lapidus R.L., Maciunas R.J., Jennings M.T., Moots P.L., et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995, 195:47-52.
28. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008, 10:1-18.
29. 18F] fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging. 2006, 33:932-939.
30. 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl Med Commun. 2007, 28:431-439.
31. 201Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis. Eur J Nucl Med Mol Imaging. 2004, 31:1237-1243.
32. Law M., Cha S., Knopp E.A., Johnson G., Arnett J., Litt A.W. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology. 2002, 222:715-721.
33. Chiang I.C., Hsieh T.J., Chiu M.L., Liu G.C., Kuo Y.T., Lin W.C. Distinction between pyogenic brain abscess and necrotic brain tumour using 3-tesla MR spectroscopy, diffusion and perfusion imaging. Br J Radiol. 2009, 82:813-820.
34. Chiang I.C., Kuo Y., Lu C., Yeung K., Lin W., Sheu F.O., et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology. 2004, 46:619-627.
35. Holmes T.M., Petrella J.R., Provenzale J.M. Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. AJR Am J Roentgenol. 2004, 183:1247-1252.
36. Ernst T.M., Chang L., Witt M.D., Aronow H.A., Cornford M.E., Walot I., et al. Cerebral toxoplasmosis and lymphoma in AIDS: perfusion MR imaging experience in 13 patients. Radiology. 1998, 208:663-669.
37. Maschke M., Kastrup O., Forsting M., Diener H. Update on neuroimaging in infectious central nervous system disease. Curr Opin Neurol. 2004, 17:475-480.
38. Asari S., Makabe T., Katayama S., Itoh T., Tsuchida S., Ohmoto T. Assessment of the pathological grade of astrocytic gliomas using an MRI score. Neuroradiology. 1994, 36:308-310.
39. Padma M.V., Said S., Jacobs M., Hwang D.R., Dunigan K., Satter M., et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003, 64:227-237.
40. 11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005, 103:498-507.
41. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009, 71:242-248.
42. Saga T., Kawashima H., Araki N., Takahashi J.A., Nakashima Y., Higashi T., et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med. 2006, 31:774-780.
43. Möller-Hartmann W., Herminghaus S., Krings T., Marquardt G., Lanfermann H., Pilatus U., et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology. 2002, 44:371-381.
44. Cerezo JJ, Villegas R, Llanos A, Rodríguez R, Vivancos J. Resonancia magnética perfusión en la diferenciación de los gliomas cerebrales. Metaanálisis y evaluación económica. Agencia de evaluación de tecnologías sanitarias de Andalucía. Ministerio de Sanidad y Consumo; 2008.
45. Cho S.K., Na D.G., Ryoo J.W., Roh H.G., Moon C.H., Byun H.S., et al. Perfusion MR imaging: clinical utility for the differential diagnosis of various brain tumors. Korean J Radiol. 2002, 3:171-179.
46. Arvinda H.R., Kesavadas C., Sarma P.S., Thomas B., Radhakrishnan V.V., Gupta A.K., et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol. 2009, 94:87-96.
47. Server A, Kulle B, Gadmar OB, Josefsen R, Kumar T, Nakstad PH. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas. Eur J Radiol (en prensa).
48. Smits A., Westerberg E., Ribom D. Adding (11)C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging. 2008, 35:65-71.
49. Law M., Oh S., Babb J.S., Wang E., Inglese M., Zagzag D., et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. Radiology. 2006, 238:658-667.
50. Sadeghi N., Salmon I., Tang B.N., Denolin V., Levivier M., Wikler D., et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging. 2006, 24:989-994.
51. Hermann E.J., Hattingen E., Krauss J.K., Marquardt G., Pilatus U., Franz K., et al. Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg. 2008, 86:300-307.
52. Maia A.C., Malheiros S.M., da Rocha A.J., Stvale J.N., Guimares I.F., Borges L.R., et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg. 2004, 101:970-976.
53. Pirotte B., Goldman S., Dewitte O., Massager N., Wikler D., Lefranc F., et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006, 104:238-253.
54. Young R.J., Brennan N., Fraser J.F., Brennan C. Advanced imaging in brain tumor surgery. Neuroimaging Clin N Am. 2010, 20:311-335.
55. Clark C.A., Barrick T.R., Murphy M.M., Bell B.A. White matter fiber tracking in patients with space-occupying lesions of the brain: a new technique for neurosurgical planning?. Neuroimage. 2003, 20:1601-1608.
56. Krishnan R., Raabe A., Hattingen E., Szelényi A., Yahya H., Hermann E., et al. Functional magnetic resonance imaging-integrated neuronavigation: correlation between lesion-to-motor cortex distance and outcome. Neurosurgery. 2004, 55:904-914.
57. Robles S.G., Gatignol P., Lehéricy S., Duffau H. Long-term brain plasticity allowing a multistage surgical approach to World Health Organization Grade II gliomas in eloquent areas. J Neurosurg. 2008, 109:615-624.
58. Thomas B., Sunaert S. Diffusion tensor imaging: technique, clinical and research applications. Rivista di Neuroradiologia. 2005, 18:419-435.
59. 11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005, 63:64-74.
60. 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009, 73:479-485.
61. Graves E.E., Nelson S.J., Vigneron D.B., Chin C., Verhey L., McDermott M., et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery. 2000, 46:319-326.
62. Krishnan A.P., Asher I.M., Davis D., Okunieff P., O'Dell W.G. Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for primary brain tumors. Int J Radiat Oncol Biol Phys. 2008, 71:1553-1562.
63. Smith J.S., Cha S., Mayo M.C., McDermott M.W., Parsa A.T., Chang S.M., et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg. 2005, 103:428-438.
64. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006, 47:904-911.
65. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med. 2006, 47:393-403.
66. 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging. 2008, 35:966-975.
67. Dhermain F.G., Hau P., Lanfermann H., Jacobs A.H., van den Bent M.J. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet neurology. 2010, 9:906-920.
68. Gerstner E.R., Batchelor T. Imaging and response criteria in gliomas. Curr Opin Oncol. 2010, 22:598-603.
69. Wang S.X., Boethius J., Ericson K. FDG-PET on irradiated brain tumor: ten years' summary. Acta Radiol. 2006, 47:85-90.
70. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008, 49:694-699.
71. 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005, 32:39-51.
72. Berkhof J., Postma T.J., Hoekstra O.S., Barkhof F., Heimans J.J. Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging. 2006, 33:222-227.
73. Graves E.E., Nelson S.J., Vigneron D.B., Verhey L., McDermott M., Larson D., et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol. 2001, 22:613-624.
74. Tomura N., Narita K., Izumi J., Suzuki A., Anbai A., Otani T., et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr. 2006, 30:496-500.